RE:Best in class 2and 3 year dataThat's right!
We are headed for an absolute 21.5 % CR rate at 3 years!
(35.6% of the 60.3% CR at any time patients)
More than one fifth of all BCG unresponsive NMIBC patients will be complwtely cured after only 1 or 2 Ruvidar PDT treatments.
It's hard to see how this will not be the first treatment urological oncologists will try if they have the best interests of their patients at heart.
enriquesuave wrote: so far we beat all competitors on 2 and 3 year data and by far. J&J tar 200 is down to 4.7% at 3 years and we are aiming for 21.4% as per Kaplan Meyer projections so far.. This shows how all other treatments show rapidly declining CR rates once they stop treating. We also beat 2 years data of recently approved combination treatment Anktiva/ BCG. 24%% vs 25.6% for us based on Kaplan Meyer projection. Can the FDA give us AA or even full approval right away?